Cargando…

A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazarbashi, Shouki, Su, Wen-Pin, Wong, Siew W., Singarachari, Ramanujam A., Rawal, Sudhir, Volkova, Maria I., Bastos, Diogo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593077/
https://www.ncbi.nlm.nih.gov/pubmed/34236692
http://dx.doi.org/10.1007/s40487-021-00160-6
_version_ 1784599634868436992
author Bazarbashi, Shouki
Su, Wen-Pin
Wong, Siew W.
Singarachari, Ramanujam A.
Rawal, Sudhir
Volkova, Maria I.
Bastos, Diogo A.
author_facet Bazarbashi, Shouki
Su, Wen-Pin
Wong, Siew W.
Singarachari, Ramanujam A.
Rawal, Sudhir
Volkova, Maria I.
Bastos, Diogo A.
author_sort Bazarbashi, Shouki
collection PubMed
description The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC.
format Online
Article
Text
id pubmed-8593077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-85930772021-12-02 A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries Bazarbashi, Shouki Su, Wen-Pin Wong, Siew W. Singarachari, Ramanujam A. Rawal, Sudhir Volkova, Maria I. Bastos, Diogo A. Oncol Ther Review The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has evolved considerably with the introduction of newer agents, such as poly-ADP ribose polymerase (PARP) inhibitors targeting DNA damage repair mutations. Combining and sequencing novel and existing therapies appropriately is necessary for optimizing the management of mCRPC and ensuring better treatment outcomes. The purpose of this review is to provide evidence-based answers to key clinical questions on treatment selection, treatment sequencing patterns, and factors influencing treatment decisions in the management of mCRPC in the era of PARP inhibitors. This article can also serve as a comprehensive guide to clinicians for optimizing genetic testing and counseling and management of patients with mCRPC. Although the PROfound study has validated the concept of PARP sensitivity across multiple genes associated with homologous recombination repair (HRR) in mCRPC and highlighted the importance of genomic testing in this at-risk patient population, it still remains unclear how patients with rarer HRR mutations will respond to PARP inhibitors. Therefore, real-world data obtained through registry-based randomized controlled trials in the future may help produce robust scientific evidence for supporting optimal clinician decision-making in the management of mCRPC. Springer Healthcare 2021-07-08 /pmc/articles/PMC8593077/ /pubmed/34236692 http://dx.doi.org/10.1007/s40487-021-00160-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Bazarbashi, Shouki
Su, Wen-Pin
Wong, Siew W.
Singarachari, Ramanujam A.
Rawal, Sudhir
Volkova, Maria I.
Bastos, Diogo A.
A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
title A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
title_full A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
title_fullStr A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
title_full_unstemmed A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
title_short A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
title_sort narrative review of implementing precision oncology in metastatic castration-resistant prostate cancer in emerging countries
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593077/
https://www.ncbi.nlm.nih.gov/pubmed/34236692
http://dx.doi.org/10.1007/s40487-021-00160-6
work_keys_str_mv AT bazarbashishouki anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT suwenpin anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT wongsieww anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT singarachariramanujama anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT rawalsudhir anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT volkovamariai anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT bastosdiogoa anarrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT bazarbashishouki narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT suwenpin narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT wongsieww narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT singarachariramanujama narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT rawalsudhir narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT volkovamariai narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries
AT bastosdiogoa narrativereviewofimplementingprecisiononcologyinmetastaticcastrationresistantprostatecancerinemergingcountries